A University of Calgary study led by members of the Arnie Charbonneau Cancer Institute, published in Nature Medicine, takes a closer look at why patients often relapse after immunotherapy by studying how the myeloma cells adapt to treatment.  By understanding how the cancer builds resistance, future treatments can be designed to take this into account with the goal of preventing another relapse.

A research paper by scientists at Gongli Hospital of Pudong New Area presented developed a sonodynamic nanoplatform that simultaneously eradicates primary breast tumors via ferroptosis and apoptosis and blocks their spread to bone tissues.

The research paper, published on Mar 23, 2026 in the journal Cyborg and Bionic Systems.

Colorectal cancer often returns not because the main tumor survives, but because a small population of stem-like cancer cells can resist treatment, seed new growth, and drive aggressive spread.

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30%. Chemotherapy alone suffers from off‑target toxicity and drug resistance. Immunotherapy offers precision and durable effects but shows limited efficacy as monotherapy. Combining chemotherapy with immunotherapy is emerging as a promising paradigm. This review summarizes the rationale and advances of combining immune checkpoint inhibitors, CAR‑T, CAR‑NK, CAR‑macrophage therapies, antibody‑drug conjugates, bispecific antibodies, and cancer vaccines with chemotherapy for AML. We discuss preclinical and clinical progress, core challenges (off‑target toxicity, tumor heterogeneity, variable efficacy), and future directions toward precision medicine.

A global review of liver cancer trends using GLOBOCAN 2022 and Global Burden of Disease data reveals a shift from viral hepatitis to metabolic disease as a leading cause. While incidence and mortality remain high, particularly in China, improved vaccination and treatment have reduced virus-related cases. Rising obesity and lifestyle risks now drive new cases. The study highlights prevention, early detection, and AI-driven care as critical strategies to curb future liver cancer burden worldwide.

Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may soon help patients live longer.

Oregon Health & Science University has received more than $9 million in National Institutes of Health funding to develop advanced microphysiologic models — also known as organs‑on-a-chip — that recreate how cancers grow, spread and respond to treatment within bone and bone‑associated tissues.